Search Bar & Filters
Found 60 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying patients with low-risk intermediate-stage nasopharyngeal carcinoma who have responded well to induction chemotherapy and have undetectable levels of plasma EBV-DNA. The trial compares two doses of radiotherapy targeting a specific low-risk area to evaluate their effects on survival, side effects, and quality of life. This phase 3 randomized study aims to find out if lower-dose radiotherapy can maintain treatment success while reducing toxicities related to treatment. Participants receive either reduced-dose radiotherapy 40.2Gy or conventional-dose radiotherapy 49.2Gy to the low-risk target volume called CTV2. Both groups undergo full-course immunotherapy with the PD-1 monoclonal antibody Tislelizumab, administered every three weeks, totaling 12 courses through induction, radiotherapy, and maintenance phases. Induction chemotherapy using a cisplatin-based regimen is given before radiotherapy. Treatment continues until toxicity, progression, withdrawal, or completion of planned courses. During the study, patients will be monitored for progression-free survival and serious adverse events over three years. Secondary measures include metastasis-free survival, relapse-free survival, overall survival, tumor response rates, and quality of life assessments using standard questionnaires over three years. Safety and effectiveness will be evaluated through imaging, laboratory tests, and clinical evaluations. The study enrollment includes adults aged 18 to 75 years, and the follow-up will provide information on long-term outcomes and treatment impact.
Actively Recruiting
Researchers are evaluating the tolerability, safety, and early effectiveness of T3011 in adults with advanced melanoma. This clinical study is designed as a phase IbIIa trial to understand how participants with measurable melanoma lesions respond to this treatment. The study is led by Shanghai Pharmaceuticals Holding Co., Ltd and focuses on treatment outcomes over approximately two years. Participants receive T3011 delivered directly into the tumor every two weeks. This treatment period is followed by ongoing monitoring to assess responses and any side effects. The trial includes a single group of participants all receiving T3011, without a comparison placebo or alternative treatment group. Throughout the study, participants undergo various assessments including laboratory tests and evaluations of tumor response. Researchers measure treatment-emergent adverse events and objective response rate as primary outcomes, along with disease control rate, remission duration, progression-free survival, and overall survival as secondary outcomes. The total study duration is approximately two years, during which safety and efficacy are closely monitored.
Actively Recruiting
Researchers are evaluating the efficacy and safety of TQB6411 for injection in adults with advanced lung cancer. This phase IbII clinical trial aims to find the recommended phase II dosage and assess how well the treatment works in shrinking tumors or controlling the disease. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and focuses on patients aged 18 to 75 years with confirmed lung cancer. Participants will receive TQB6411 injections either every 21 days or every 28 days as treatment cycles. The study involves only one treatment group where all participants receive TQB6411. Each cycle of treatment is followed by assessments to monitor response and safety. The trial includes dose evaluation and efficacy measurement over several months, with extended follow-up for survival and side effects lasting up to three years. During the study, participants will undergo medical evaluations including laboratory tests, imaging scans to measure tumors, and monitoring of adverse events. Blood samples will be taken to study drug levels and antibodies. The main outcomes measured include tumor response rates, disease control, duration of response, progression-free and overall survival. Safety is closely monitored throughout the study. The total participation time may last up to three years, including treatment and follow-up visits.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of pegmolesatide, a long-acting erythropoiesis-stimulating agent ESA, in patients with renal anemia who are currently treated with hypoxia-inducible factor prolyl hydroxylase inhibitors HIF-PHIs. This trial aims to explore the safety and effectiveness of switching from HIF-PHIs to pegmolesatide, addressing the current need for longer-acting and safe medications. The study is a multi-center, prospective, open-label, randomized parallel-controlled trial enrolling 96 dialysis chronic kidney disease patients with anemia. Participants are divided into two groups based on their current weekly Roxadustat dose a low-dose cohort 210 mg and a high-dose cohort >210 mg and 360 mg. Within each cohort, patients are randomly assigned to receive pegmolesatide at different initial doses 2 mg, 4 mg, or 6 mg administered subcutaneously once every 4 weeks. The dose may be adjusted according to the drugs instructions. The treatment period lasts 12 weeks, followed by a 16-week follow-up period. During the study, researchers will monitor hemoglobin levels and other blood parameters at various intervals to assess the effects of pegmolesatide. Patients will undergo assessments including hemoglobin tests, red blood cell counts, and safety monitoring for adverse events. The primary measurement is the change in mean hemoglobin levels from baseline to 12 and 16 weeks. The total participation time for each patient is 28 weeks, including treatment and follow-up.
Actively Recruiting
Researchers are evaluating the real-world effectiveness and safety of Trastuzumab Deruxtecan T-DXd in patients with unresectable or metastatic HER2-positive or HER2-low breast cancer. This observational study focuses on patients who have previously received anti-HER2 treatments or systemic therapy and aims to understand treatment outcomes, patient characteristics, and tolerability over time. The study is sponsored by Daiichi Sankyo and collects detailed clinical and patient-reported data to provide insights into treatment patterns and safety. Participants are grouped into two cohorts those with HER2-positive breast cancer who have had one or more anti-HER2 regimens, and those with HER2-low breast cancer who have received prior systemic therapy or experienced early recurrence after adjuvant chemotherapy. All participants are starting or have recently started T-DXd treatment according to approved labeling in China. The study observes these patients from the start of treatment until study end, death, withdrawal, loss to follow-up, or closure. During the study, researchers will track time to next treatment or death, treatment duration, dosing changes, safety events, and patient-reported tolerability using questionnaires and symptom diaries. Follow-up lasts up to 36 months with ongoing data collection on clinical characteristics, treatment patterns, and safety management. This design allows for a comprehensive view of how T-DXd performs in routine clinical practice for this patient population.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of an inavolisib-based regimen in people with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. This study focuses on individuals in China who have completed adjuvant endocrine therapy and now have disease progression. The study aims to observe real-world outcomes to better understand treatment results in routine clinical practice. Participants will receive inavolisib according to their physicians discretion, following local clinical guidelines and labeling. Some participants may also be treated with palbociclib and fulvestrant as part of their standard care, with treatment decisions and timing based on clinical need. The study is observational, meaning treatments are given as part of normal care rather than assigned by the study, and participants will be monitored for up to approximately 36 months. During the study, participants will be followed to assess progression-free survival, tumor response, duration of response, time to treatment discontinuation, and other real-world outcomes related to disease progression and treatment use. Safety will be monitored by tracking adverse events. Researchers will collect data from medical records and other routine assessments during this period. The total participation time may extend up to about three years, allowing long-term observation of treatment effects and tolerability.
Actively Recruiting
Researchers are evaluating the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of plonmarlimab in adults with acute gouty arthritis. This phase II, multicenter, randomized, double-blind, double-dummy, active-controlled study aims to compare plonmarlimab against an active comparator to understand its effects on pain reduction as measured by the Visual Analogue Scale VAS within 72 hours after dosing. An interim analysis after the first 60 participants will guide potential adjustments to sample size and treatment group selection. Participants are randomly assigned to one of three groups plonmarlimab 3 mgkg as a single intravenous infusion, plonmarlimab 6 mgkg as a single intravenous infusion, or compound betamethasone 7 mg as a single intramuscular injection. The study includes a double-dummy design with placebos matching both active treatments. The primary focus is on the initial single dose administration, with no further dosing detailed. Participants will be assessed for pain intensity using the VAS score at 72 hours after the initial dose. The study collects data on treatment safety, tolerability, pharmacokinetics, and immunogenicity. The trial duration and visit schedule beyond the primary outcome are not specified, but participants are monitored closely during the initial treatment period to evaluate study endpoints and safety.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.
1-10 of 60
1